A retrospective study of TNF-inhibitors, secukinumab and ustekinumab in subclinical (non-tender) dactylitis in patients with psoriatic arthritis
Latest Information Update: 22 Jun 2021
At a glance
- Drugs Secukinumab (Primary) ; Tumour necrosis factor inhibitors (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 22 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.